Latham & Watkins Advised RTW Investments On US$100 Million Royalty Funding Agreement With Candel Therapeutics

Latham & Watkins Advised RTW Investments on US$100 Million Royalty Funding Agreement With Candel Therapeutics

Latham & Watkins advised RTW Investments on US$100 Million Royalty Funding Agreement with Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, has announced a US$100 million royalty funding agreement with funds managed by RTW Investments, LP (RTW), subject to FDA approval of aglatimagene besadenovec (CAN-2409) in intermediate- to high-risk, localized prostate cancer.

The Latham & Watkins LLP deal team led by Bay Area Todd Trattner (Partner), with Axel Magnusson (Associate), and Ian Drazen (Associate). Advice was also provided on tax matters by Los Angeles Eric Cho (Partner), with Sam Yang (Associate).

Click to know more about Latham & Watkins

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.